WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2024

Hedge fundSEC filingsCompare with another fundHoldings as of 2024-09-30, filed 2024-11-14

Avidity Partners Management LP disclosed 81 US equity positions worth $2.0bn in its Q3 2024 13F filing. Its largest position is BSX at 4.1% of the reported book, followed by DNTH and ISRG. Versus Q2 2024 it opened 19 new positions, added to 12, reduced 37 and exited 23.

$2.0bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
81
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
4.1%
Largest position
The largest single position as a share of the reported equity book.
32.0%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
49
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2024: 19 new, 12 added, 37 reduced, 23 exited

50 of 81
BSX BOSTON SCIENTIFIC CORPHealthcare4.1%$80.6m962,000−18%reduced
DNTH DIANTHUS THERAPEUTICS INCHealthcare4.1%$79.9m2.92m0.0%held
ISRG INTUITIVE SURGICAL INCHealthcare3.7%$72.8m148,200−40%reduced
NTRA NATERA INCHealthcare3.6%$70.6m556,400−27%reduced
CGON CG ONCOLOGY INCHealthcare3.2%$62.5m1.66m+28%added
ACHC ACADIA HEALTHCARE COMPANY INHealthcare3.2%$62.5m985,000−12%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.7%$53.0m460,000−6.3%reduced
UNH UNITEDHEALTH GROUP INCHealthcare2.6%$51.1m87,400–new
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.4%$48.0m431,000−21%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.4%$47.3m2.46m−26%reduced
CATX PERSPECTIVE THERAPEUTICS INC–2.3%$46.0m3.44m+13%added
GKOS GLAUKOS CORPHealthcare2.3%$44.9m344,900+54%added
IDYA IDEAYA BIOSCIENCES INCHealthcare2.2%$43.5m1.37m+23%added
INSM INSMED INCHealthcare2.2%$43.2m592,000+38%added
TMO THERMO FISHER SCIENTIFIC INCHealthcare2.2%$42.4m68,600−14%reduced
THC TENET HEALTHCARE CORPHealthcare2.1%$42.0m253,000−32%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare2.1%$41.8m752,000−22%reduced
HUM HUMANA INCHealthcare2.1%$41.1m129,700–new
EXK EXACT SCIENCES CORPBasic Materials2.0%$40.1m588,000+74%added
ILMN ILLUMINA INCHealthcare1.9%$38.1m292,000−39%reduced
ARVN ARVINAS INCHealthcare1.9%$36.9m1.50m−50%reduced
RVMD REVOLUTION MEDICINES INCHealthcare1.8%$35.8m790,000+4.6%added
CNTA CENTESSA PHARMACEUTICALS PLC–1.7%$34.1m2.13m–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.7%$32.6m1.80m+11%added
XENE XENON PHARMACEUTICALS INCHealthcare1.6%$32.2m818,000+8.5%added
AVTR AVANTOR INCHealthcare1.6%$31.9m1.24m−60%reduced
2655787D BLUEPRINT MEDICINES CORP–1.5%$29.1m315,000−18%reduced
MIRM MIRUM PHARMACEUTICALS INCHealthcare1.5%$28.5m731,1040.0%held
SGRY SURGERY PARTNERS INCHealthcare1.4%$26.7m827,000−37%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare1.4%$26.6m296,100−21%reduced
DHR DANAHER CORP DELHealthcare1.3%$26.4m95,000−37%reduced
JANX JANUX THERAPEUTICS INCHealthcare1.3%$25.5m562,000−33%reduced
NMRA NEUMORA THERAPEUTICS INC.Healthcare1.2%$23.8m1.80m0.0%held
KYMR KYMERA THERAPEUTICS INCHealthcare1.2%$23.7m500,000–new
BHVN BIOHAVEN LTDHealthcare1.2%$23.2m465,000+3.3%added
BMRN BIOMARIN PHARMACEUTICAL INCHealthcare1.1%$22.5m320,000–new
ARGX ARGENX SEHealthcare1.1%$20.7m38,200−37%reduced
INCY INCYTE CORPHealthcare1.0%$20.4m308,110−42%reduced
ABBV ABBVIE INCHealthcare1.0%$19.7m100,000−64%reduced
ORKA ORUKA THERAPEUTICS INCHealthcare1.0%$19.4m790,926–new
GPCR STRUCTURE THERAPEUTICS INCHealthcare1.0%$18.9m430,900−60%reduced
NGNE NEUROGENE INCHealthcare0.9%$17.8m425,041−42%reduced
430 TERNS PHARMACEUTICALS INC–0.9%$17.8m2.13m–new
ASND ASCENDIS PHARMA A/SHealthcare0.9%$17.8m119,000–new
BNTX BIONTECH SEHealthcare0.9%$17.2m145,000–new
ITCIEUR INTRA-CELLULAR THERAPIES INC–0.9%$17.0m233,000−42%reduced
KROS KEROS THERAPEUTICS INCHealthcare0.9%$17.0m293,200−15%reduced
DXCM DEXCOM INCHealthcare0.8%$16.1m240,000−7.3%reduced
ORIC ORIC PHARMACEUTICALS INCHealthcare0.8%$14.8m1.45m–new
NEWAMSTERDAM PHARMA COMPANY no ticker–0.8%$14.8m889,700+59%added

Exited since Q2 2024

23 rows
CI THE CIGNA GROUP2.6%$61.0m
ALNY ALNYLAM PHARMACEUTICALS INC2.3%$53.9m
REGN REGENERON PHARMACEUTICALS2.1%$50.4m
MRK MERCK & CO. INC1.7%$40.2m
UTHR UNITED THERAPEUTICS CORP DEL1.5%$35.0m
LNTH LANTHEUS HLDGS INC1.0%$23.3m
PCVX VAXCYTE INC0.9%$21.4m
JSPR JASPER THERAPEUTICS INC0.8%$17.8m
LEGN LEGEND BIOTECH CORP0.7%$17.6m
GILD GILEAD SCIENCES INC0.7%$17.5m
AZN ASTRAZENECA PLC0.7%$16.0m
CRBP CORBUS PHARMACEUTICALS HLDGS0.4%$9.8m
TYRA TYRA BIOSCIENCES INC0.3%$6.0m
PATH UIPATH INC0.2%$4.6m
SYRE SPYRE THERAPEUTICS INC0.2%$4.6m
IMTX IMMATICS N.V0.2%$4.6m
IONS IONIS PHARMACEUTICALS INC0.2%$4.4m
ABIOEUR ARCA BIOPHARMA INC0.2%$3.8m
NTLA INTELLIA THERAPEUTICS INC0.2%$3.8m
COLL COLLEGIUM PHARMACEUTICAL INC0.2%$3.8m
ACIU AC IMMUNE SA0.1%$3.3m
WVE WAVE LIFE SCIENCES LTD0.07%$1.7m
NUVATION BIO INC no ticker0.0%$1.9k

Sector mix

  • Healthcare87.8%
  • Unclassified10.2%
  • Basic Materials2.0%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters